Asmaa Hamoda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Asmaa Hamoda has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Alaa ElHaddad
Children’s Cancer Hospital Egypt 57357 and National Cancer Institute, Cairo, Egypt
2 shared publicationsAmr Elnashar
Department of Clinical Research, Children Cancer Hospital of Egypt
2 shared publicationsEmad Moussa
Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo
2 shared publicationsEman Khorshed
Department of Pathology, National Cancer Institute, Cairo University
2 shared publicationsHala Taha
Children’s Cancer Hospital Egypt 57357 and National Cancer Institute, Cairo, Egypt
2 shared publicationsIman Zaky
Children’s Cancer Hospital Egypt 57357 and National Cancer Institute, Cairo, Egypt
2 shared publications
Latest Publications
- 22 August 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 46 (7) , e493-e500
PET/CT Response Assessment in Pediatric Hodgkin Lymphoma: Does Deauville Score 3 Reflect Negativity?
Background: FDG PET is required for the staging and response evaluation of pediatric Hodgkin lymphoma. This study aimed to evaluate the outcomes of pediatric patients with Hodgkin’s lymphoma based on interim PET CT assessments of early response following second-cycle chemotherapy using the Deauville score (DS). It also determines whether DS–3 is providing an adequate or inadequate response. Methods: We conducted a retrospective cohort study including 504 pediatric patients with classic Hodgkin lymphoma who were treated with chemotherapy based on the Euro-Net protocol at the Children Cancer Hospital Egypt from March 2019 till the end of October 2022. Results: Patients with adequate response DS 1/2 and DS 3 showed nearly the same 3-year event-free survival (EFS) of 91.9% and 91.5%, respectively, compared with those patients with inadequate response DS 4/5, who showed an EFS of 80.4% (P=0.001). Patients with a DS 3 at interim PET evaluation were considered negative as DS 1/2. Patients of DS 3 group who did not receive radiotherapy had a much worse 3-year EFS by the existence of positive B symptoms, an ESR>30, or an advanced stage. Radiation therapy did not improve the 3-year EFS in patients with an inadequate response (DS4/5) and poor prognostic characteristics. They still need more advanced treatment. Conclusion: DS 1/2 and DS 3 had about the same 3-year EFS, which is better than the 3-year EFS of patients with DS 4/5. Therefore, we can classify DS 3 as having negative FDG PET CT uptake.
- 22 August 2024
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 46 (7) , e493-e500
PET/CT Response Assessment in Pediatric Hodgkin Lymphoma: Does Deauville Score 3 Reflect Negativity?
Background: FDG PET is required for the staging and response evaluation of pediatric Hodgkin lymphoma. This study aimed to evaluate the outcomes of pediatric patients with Hodgkin’s lymphoma based on interim PET CT assessments of early response following second-cycle chemotherapy using the Deauville score (DS). It also determines whether DS–3 is providing an adequate or inadequate response. Methods: We conducted a retrospective cohort study including 504 pediatric patients with classic Hodgkin lymphoma who were treated with chemotherapy based on the Euro-Net protocol at the Children Cancer Hospital Egypt from March 2019 till the end of October 2022. Results: Patients with adequate response DS 1/2 and DS 3 showed nearly the same 3-year event-free survival (EFS) of 91.9% and 91.5%, respectively, compared with those patients with inadequate response DS 4/5, who showed an EFS of 80.4% (P=0.001). Patients with a DS 3 at interim PET evaluation were considered negative as DS 1/2. Patients of DS 3 group who did not receive radiotherapy had a much worse 3-year EFS by the existence of positive B symptoms, an ESR>30, or an advanced stage. Radiation therapy did not improve the 3-year EFS in patients with an inadequate response (DS4/5) and poor prognostic characteristics. They still need more advanced treatment. Conclusion: DS 1/2 and DS 3 had about the same 3-year EFS, which is better than the 3-year EFS of patients with DS 4/5. Therefore, we can classify DS 3 as having negative FDG PET CT uptake.
- Open Access
- 24 June 2024
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-8
High risk Langerhans cell histiocytosis in children: the role of salvage in improving the outcome. A single center experience
Background: In pediatric multi-system high risk organs (RO +) Langerhans cell histiocytosis (LCH), failing 1st line treatment has the highest mortality. We aim to present the outcome of failure of 1st line whether due to disease progression (DP) at end of induction or reactivation (REA) after initial better status response. Patients and methods: Sixty-seven RO + LCH patients with hemopoietic, hepatic or splenic involvement, treated between 2007 and 2019 were retrospectively analyzed. The median follow-up (IQR) is 6 years (4–8.8 y).They were subjected to 2 eras of treatment; one with salvage by 2-Cda based regimen (2-CdABR) and another without. Results: Of 67 patients, M/F 40/27, median age 1.74 y (0.2–10 y), 42 failed 1st line (62.7%). Of them DP n = 22 (52%) and REA n = 20 (48%). Of those with DP, 9/22 patients received 2-CdABR, where 5 survived in better status. While the remaining 13 did not receive 2-CdABR and all of them died. Otherwise, of those with REA, 12/20 reactivated on RO + mode. Of them, 8/12 received 2-CdABR, where only one survived in better status and the remaining 4 received vinblastine-based regimen,where 2 died and 2 were rescued. RO + 5-year overall survival (OS) was 65% (CI 95% 54 -78) while the event free survival (EFS) 36% (26.3—50.1). The OS of DP 27% (14–54) versus REA 67% (49–93) p 0.004. OS of DP with 2-CdABR 56% (31–97.7) versus 8% without (2–51), p < 0.001. While OS of REA with 2-CdABR 38% (13–100) versus 74% without (53–100) p 0.7. Conclusion: Survival of RO + remains limited. Failure of 1st line in RO + due to DP carries worse prognosis in relation to REA. In DP those who were not salvaged by 2-CdABR, showed dismal outcome. This could not be shown when applied in REA.
- 24 June 2024
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-8
Open AccessHigh risk Langerhans cell histiocytosis in children: the role of salvage in improving the outcome. A single center experience
Background: In pediatric multi-system high risk organs (RO +) Langerhans cell histiocytosis (LCH), failing 1st line treatment has the highest mortality. We aim to present the outcome of failure of 1st line whether due to disease progression (DP) at end of induction or reactivation (REA) after initial better status response. Patients and methods: Sixty-seven RO + LCH patients with hemopoietic, hepatic or splenic involvement, treated between 2007 and 2019 were retrospectively analyzed. The median follow-up (IQR) is 6 years (4–8.8 y).They were subjected to 2 eras of treatment; one with salvage by 2-Cda based regimen (2-CdABR) and another without. Results: Of 67 patients, M/F 40/27, median age 1.74 y (0.2–10 y), 42 failed 1st line (62.7%). Of them DP n = 22 (52%) and REA n = 20 (48%). Of those with DP, 9/22 patients received 2-CdABR, where 5 survived in better status. While the remaining 13 did not receive 2-CdABR and all of them died. Otherwise, of those with REA, 12/20 reactivated on RO + mode. Of them, 8/12 received 2-CdABR, where only one survived in better status and the remaining 4 received vinblastine-based regimen,where 2 died and 2 were rescued. RO + 5-year overall survival (OS) was 65% (CI 95% 54 -78) while the event free survival (EFS) 36% (26.3—50.1). The OS of DP 27% (14–54) versus REA 67% (49–93) p 0.004. OS of DP with 2-CdABR 56% (31–97.7) versus 8% without (2–51), p < 0.001. While OS of REA with 2-CdABR 38% (13–100) versus 74% without (53–100) p 0.7. Conclusion: Survival of RO + remains limited. Failure of 1st line in RO + due to DP carries worse prognosis in relation to REA. In DP those who were not salvaged by 2-CdABR, showed dismal outcome. This could not be shown when applied in REA.
- Open Access
- 1 May 2024
- Published by AME Publishing Company in Annals of Lymphoma
- Vol. 8, 3
Pediatric Infradiaphragmatic Hodgkin’s lymphoma: a unique identity
Background: Infra-diaphragmatic Hodgkin’s lymphoma (IDHL) is a rare disease. The prognostic impact of infra-diaphragmatic localization of this lymphoma is controversial. We aim to evaluate the clinic-pathologic features and outcome of IDHL. Methods: Between 2007 and 2020, all patients with histologically confirmed stage I/II IDHL were retrospectively evaluated including clinical presentation, initial lab work, radiological findings, response to initial treatment and their outcome in comparison to stage I/II supra-diaphragmatic HL (SDHL). Results: Among 991 Hodgkin’s lymphoma (HL) staged I/II, there were 35 IDHL (3.5%) patients with male to female ratio 2.5:1, median age of 10.1 years, 34.3% (12/35) of cases were histologically nodular lymphocytic predominant HL (NLPHL) while 37.1% (13/35) were classical HL (CHL) of mixed cellularity (MC) type, 34.3% (12/35) of patients presented with B symptoms. In 57% of cases erythrocyte sedimentation rate (ESR) was less than 30, 20% (7/35) of patients relapsed. Overall survival (OS) was 87.8% while relapse free survival (RFS) was 76.2% at 5 years, OS and RFS of the patients with adequate interim positron emission tomography/computed tomography (PET/CT) response were higher than those with inadequate response at 5 years (Pvs. 98.2% for supra-diaphragmatic) while RFS according to diaphragmatic site was also statistically significant (PConclusions: Although IDHL cases do not carry high risk features still this category of the patients has lower OS and RFS in comparison to supra-diaphragmatic cases at initial presentation making infra-diaphragmatic site by itself a bad prognostic factor.
- 1 May 2024
- Published by AME Publishing Company in Annals of Lymphoma
- Vol. 8, 3
Open AccessPediatric Infradiaphragmatic Hodgkin’s lymphoma: a unique identity
Background: Infra-diaphragmatic Hodgkin’s lymphoma (IDHL) is a rare disease. The prognostic impact of infra-diaphragmatic localization of this lymphoma is controversial. We aim to evaluate the clinic-pathologic features and outcome of IDHL. Methods: Between 2007 and 2020, all patients with histologically confirmed stage I/II IDHL were retrospectively evaluated including clinical presentation, initial lab work, radiological findings, response to initial treatment and their outcome in comparison to stage I/II supra-diaphragmatic HL (SDHL). Results: Among 991 Hodgkin’s lymphoma (HL) staged I/II, there were 35 IDHL (3.5%) patients with male to female ratio 2.5:1, median age of 10.1 years, 34.3% (12/35) of cases were histologically nodular lymphocytic predominant HL (NLPHL) while 37.1% (13/35) were classical HL (CHL) of mixed cellularity (MC) type, 34.3% (12/35) of patients presented with B symptoms. In 57% of cases erythrocyte sedimentation rate (ESR) was less than 30, 20% (7/35) of patients relapsed. Overall survival (OS) was 87.8% while relapse free survival (RFS) was 76.2% at 5 years, OS and RFS of the patients with adequate interim positron emission tomography/computed tomography (PET/CT) response were higher than those with inadequate response at 5 years (Pvs. 98.2% for supra-diaphragmatic) while RFS according to diaphragmatic site was also statistically significant (PConclusions: Although IDHL cases do not carry high risk features still this category of the patients has lower OS and RFS in comparison to supra-diaphragmatic cases at initial presentation making infra-diaphragmatic site by itself a bad prognostic factor.
- Open Access
- 22 January 2024
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 36 (1) , 1-11
Pulmonary metastatectomy in pediatric cancer patients at National Cancer Institute, Egypt: prognostic factors and outcome
Metastatic tumors account for 80% of all lung tumors in children. Wilms tumour and osteosarcoma are the most tumors of childhood that produce lung metastases. The aim of the current study is to assess the prognostic factors of pulmonary metastatectomy in pediatric solid tumours as age, number, size, site,laterality, resectability of pulmonary nodules, and number of Thoracotomies. Calculate overall survival among patients who underwent pulmonary metastatectomy. It is a retrospective study including all pediatric patients with metastatic solid tumors to lungs treated at pediatric oncology department, National Cancer Institute, Cairo University from 2008 to 2014. Fifty-five patients were included, 43 (78.2℅) patients of them had Osteosarcoma. Thirty (54.5℅)patients were male. The mean age was 15 years ranging from (4.5- 23) years. The site of primary disease was at lower limbs in 43 (78.2%) patients. All patients underwent complete surgical resection of the primary disease with negative margin, 22(51.1%) of the osteosarcoma patients did amputation with tumor necrosis less than 90%. All patients received chemotherapy and only 9 received radiation therapy. The patients were classified into four groups according to time of diagnosis of pulmonary metastasis: at time of diagnosis in 13 (21.8%) patients, within treatment in 16 (30.9%) patients, within first year follow up in 18 (32.7%) patients and detected late in 8 (14.5%) patients. Bilateral lung metastasis diagnosed by CT chest were detected in 42 (76.4%) patients. Size of metastatic nodules was ranging from (0.5 to 10 cm) with mean 3.4 cm. Number of metastatic nodules was ranging from (1 to 28) median 4.Metastatic complications were detected in 19 patients. 5-year OS was 74.8% in the study group, and 68% in osteosarcoma patients. Effect of prognostic factors as sex, time of respectability, laterality, tumor necrosis of the 1ry disease, Timing of lung metastasis, size and site of the primary, Surgical approach of metastatectomy, postoperative complications on overall survival of the studied patients was done with significant P-value of tumor necrosis of the 1ry disease and Timing of lung metastasis 0.017, 0.001 respectively. Resection of pulmonary metastases of pediatric solid tumours is a safe and effective treatment that offers better survival.
- 22 January 2024
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 36 (1) , 1-11
Open AccessPulmonary metastatectomy in pediatric cancer patients at National Cancer Institute, Egypt: prognostic factors and outcome
Metastatic tumors account for 80% of all lung tumors in children. Wilms tumour and osteosarcoma are the most tumors of childhood that produce lung metastases. The aim of the current study is to assess the prognostic factors of pulmonary metastatectomy in pediatric solid tumours as age, number, size, site,laterality, resectability of pulmonary nodules, and number of Thoracotomies. Calculate overall survival among patients who underwent pulmonary metastatectomy. It is a retrospective study including all pediatric patients with metastatic solid tumors to lungs treated at pediatric oncology department, National Cancer Institute, Cairo University from 2008 to 2014. Fifty-five patients were included, 43 (78.2℅) patients of them had Osteosarcoma. Thirty (54.5℅)patients were male. The mean age was 15 years ranging from (4.5- 23) years. The site of primary disease was at lower limbs in 43 (78.2%) patients. All patients underwent complete surgical resection of the primary disease with negative margin, 22(51.1%) of the osteosarcoma patients did amputation with tumor necrosis less than 90%. All patients received chemotherapy and only 9 received radiation therapy. The patients were classified into four groups according to time of diagnosis of pulmonary metastasis: at time of diagnosis in 13 (21.8%) patients, within treatment in 16 (30.9%) patients, within first year follow up in 18 (32.7%) patients and detected late in 8 (14.5%) patients. Bilateral lung metastasis diagnosed by CT chest were detected in 42 (76.4%) patients. Size of metastatic nodules was ranging from (0.5 to 10 cm) with mean 3.4 cm. Number of metastatic nodules was ranging from (1 to 28) median 4.Metastatic complications were detected in 19 patients. 5-year OS was 74.8% in the study group, and 68% in osteosarcoma patients. Effect of prognostic factors as sex, time of respectability, laterality, tumor necrosis of the 1ry disease, Timing of lung metastasis, size and site of the primary, Surgical approach of metastatectomy, postoperative complications on overall survival of the studied patients was done with significant P-value of tumor necrosis of the 1ry disease and Timing of lung metastasis 0.017, 0.001 respectively. Resection of pulmonary metastases of pediatric solid tumours is a safe and effective treatment that offers better survival.
- Open Access
- 6 December 2023
- Published by Springer Nature in Research Square
High Risk Langerhans Cell Histiocytosis in Children: The role of salvage in improving the outcome. A single center experience.
Background: In pediatric multi-system high risk organs (RO+) Langerhans cell histiocytosis (LCH), failing 1st line treatment has the highest mortality. Hereby we aim to present the outcome of salvage whether due to disease progression (DP) at end of induction or afterwards reactivation (REA). Sixty-seven RO+ LCH patients, treated between mid-2007 and end 2019 were retrospectively analyzed. They were subjected to the LCH III protocol era, having 1st line intermediate dose methotrexate induction (ID MTX) but without salvage by 2-Cda based regimen (2-CdABR) and that of LCH IV protocol without ID MTX but with 2-CdABR salvage. Results: Twenty-two patients showed DP. Of them 9 received 2-CdABR where 5 patients survived in better status. All the remaining 13 not receiving 2-CdABR died. Otherwise, 20 patients showed REA (RO+ mode n=12). Out of those 8 patients receiving 2-CdABR for REA RO+ mode, only one survived in better status. The overall survival (OS) of those undergoing DP was 27% CI 14-54 versus REA 67% CI 49-93 p 0.004. OS of DP with 2-CdABR was 56% CI=31-97.7 versus without 8 % CI 2-51, p<0.001. While OS of REA with 2-CdABR was 38% CI=13-100 versus without 74 % CI 53-100 p value 0.7. Conclusion: 2-CdABR rescued DP RO+LCH in relation to regimen without. Its impact on REA remains controversial in relation to other salvage regimen.
- 6 December 2023
- Published by Springer Nature in Research Square
Open AccessHigh Risk Langerhans Cell Histiocytosis in Children: The role of salvage in improving the outcome. A single center experience.
Background: In pediatric multi-system high risk organs (RO+) Langerhans cell histiocytosis (LCH), failing 1st line treatment has the highest mortality. Hereby we aim to present the outcome of salvage whether due to disease progression (DP) at end of induction or afterwards reactivation (REA). Sixty-seven RO+ LCH patients, treated between mid-2007 and end 2019 were retrospectively analyzed. They were subjected to the LCH III protocol era, having 1st line intermediate dose methotrexate induction (ID MTX) but without salvage by 2-Cda based regimen (2-CdABR) and that of LCH IV protocol without ID MTX but with 2-CdABR salvage. Results: Twenty-two patients showed DP. Of them 9 received 2-CdABR where 5 patients survived in better status. All the remaining 13 not receiving 2-CdABR died. Otherwise, 20 patients showed REA (RO+ mode n=12). Out of those 8 patients receiving 2-CdABR for REA RO+ mode, only one survived in better status. The overall survival (OS) of those undergoing DP was 27% CI 14-54 versus REA 67% CI 49-93 p 0.004. OS of DP with 2-CdABR was 56% CI=31-97.7 versus without 8 % CI 2-51, p<0.001. While OS of REA with 2-CdABR was 38% CI=13-100 versus without 74 % CI 53-100 p value 0.7. Conclusion: 2-CdABR rescued DP RO+LCH in relation to regimen without. Its impact on REA remains controversial in relation to other salvage regimen.